[¹⁷⁷Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply

Affiliations

¹ Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hofman@petermac.org.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
³ Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Comment

Michael S Hofman et al. Lancet Oncol. 2018 Aug.

. 2018 Aug;19(8):e373.

doi: 10.1016/S1470-2045(18)30534-5.

¹ Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hofman@petermac.org.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
³ Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

No abstract available

Comment on

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
[¹⁷⁷Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.
Rahbar K, Ahmadzadehfar H, Seifert R, Boegemann M. Rahbar K, et al. Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8. Lancet Oncol. 2018. PMID: 30102221 No abstract available.
[¹⁷⁷Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.
Derlin T, Schmuck S. Derlin T, et al. Lancet Oncol. 2018 Aug;19(8):e372. doi: 10.1016/S1470-2045(18)30488-1. Lancet Oncol. 2018. PMID: 30102222 No abstract available.